Looking for 852626-89-2 / Samidorphan API manufacturers, exporters & distributors?
Samidorphan manufacturers, exporters & distributors
1
89
PharmaCompass offers a list of Samidorphan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Samidorphan manufacturer or Samidorphan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Samidorphan manufacturer or Samidorphan supplier.
API | Excipient name
Samidorphan
Synonyms
852626-89-2, Alks 33, Alks-33, Samidorphan [usan], Rdc-0313-00, Chembl426084
Unique Ingredient Identifier (UNII)
7W2581Z5L8
About Samidorphan
[Olanzapine] is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes. Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent -opioid receptor antagonism, higher oral bioavailability, and a longer half-life, making it an attractive candidate for oral dosing. Although antipsychotic-induced weight gain is incompletely understood, it is thought that the opioid system plays a key role in feeding and metabolism, such that opioid antagonism may be expected to ameliorate these negative effects. Samidorphan has been shown in animal models and clinical trials to ameliorate [olanzapine]-induced weight gain and metabolic dysfunction. Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI by Alkermes Inc.